Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 17 de 17
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Exp Dermatol ; 48(6): 648-659, 2023 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-36753386

RESUMO

Dermatological diseases are widespread and have a significant impact on the quality of life of patients; however, access to appropriate care is often limited. Improved early training during medical school represents a potential upstream solution. This scoping review explores dermatology education during medical school, with a focus on identifying the factors associated with optimizing the preparation of future physicians to provide care for patients with skin disease. A literature search was conducted using online databases (Embase, MEDLINE, CINAHL and Scopus) to identify relevant studies. The Joanna Briggs Institute methodological framework for scoping reviews was used, including quantitative and qualitative data analysis following a grounded theory approach. From 1490 articles identified, 376 articles were included. Most studies were from the USA (46.3%), UK (16.2%), Germany (6.4%) and Canada (5.6%). Only 46.8% were published as original articles, with a relatively large proportion either as letters (29.2%) or abstracts (12.2%). Literature was grouped into three themes: teaching content, delivery and assessment. Core learning objectives were country dependent; however, a common thread was the importance of skin cancer teaching and recognition that diversity and cultural competence need greater fostering. Various methods of delivery and assessment were identified, including computer-aided and online, audiovisual, clinical immersion, didactic, simulation and peer-led approaches. The advantages and disadvantages of each need to be weighed when deciding which is most appropriate for a given learning outcome. The broader teaching-learning ecosystem is influenced by (i) community health needs and medical school resources, and (ii) the student and their ability to learn and perform. Efforts to optimize dermatology education may use this review to further investigate and adapt teaching according to local needs and context.


Assuntos
Dermatologia , Humanos , Ecossistema , Qualidade de Vida , Faculdades de Medicina , Aprendizagem
3.
Australas J Dermatol ; 61(4): e421-e423, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32585743

RESUMO

Eosinophilic cellulitis is a rare inflammatory skin disease of unknown aetiology, first described by George Wells in 1971 as a recurrent granulomatous dermatitis with eosinophilia. It is typically characterised by recurrent pruritic erythematous plaques, vesicles or bullae usually involving the extremities and trunk. Many cases of eosinophilic cellulitis are difficult to treat and traditionally require long course of oral steroids, resulting in steroid side effects. This case adds to the literature in that we report the use of methotrexate to treat eosinophilic cellulitis, as a safe and efficacious therapeutic alternative.


Assuntos
Celulite (Flegmão)/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Eosinofilia/tratamento farmacológico , Metotrexato/uso terapêutico , Adulto , Celulite (Flegmão)/etiologia , Feminino , Humanos
5.
J Am Acad Dermatol ; 80(4): 1168-1171, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30471314

RESUMO

The Multicenter Selective Lymphadenectomy Trials indicate that there are no overall or melanoma-specific survival advantages to performing sentinel lymph node biopsy (SLNB) followed by immediate completion lymph node dissection compared with wide excision and observation for patients with positive sentinel nodes. These results make SLNB solely a staging procedure. The role of SLNB in the management of patients with melanoma deserves reappraisal. The potential marginal benefit of SLNB beyond the clinical and pathologic features of the melanoma has not been well studied. The use of sentinel lymph node status alone to accept and stratify patients into trials or to receive adjuvant treatment is not rational.


Assuntos
Melanoma/secundário , Seleção de Pacientes , Biópsia de Linfonodo Sentinela , Linfonodo Sentinela/patologia , Neoplasias Cutâneas/patologia , Humanos , Excisão de Linfonodo , Metástase Linfática , Estadiamento de Neoplasias , Ensaios Clínicos Controlados Aleatórios como Assunto , Linfonodo Sentinela/cirurgia , Biópsia de Linfonodo Sentinela/economia , Taxa de Sobrevida , Carga Tumoral
9.
Australas J Dermatol ; 58(4): 256-258, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29064087

RESUMO

Sentinel lymph node (SLN) status has been advocated in several recently published articles as the single most valuable prognostic marker for melanoma, and of greater prognostic importance than more established parameters such as Breslow thickness. A careful examination of the evidence for these claims, however, indicates that they are not substantiated by the available data, are somewhat misleading and suggest misinterpretation of the statistical analysis of the papers to which they refer. We will examine the basis for these claims and show why they are invalid.


Assuntos
Melanoma/secundário , Linfonodo Sentinela/patologia , Neoplasias Cutâneas/patologia , Estatística como Assunto , Humanos , Metástase Linfática , Valor Preditivo dos Testes , Prognóstico , Biópsia de Linfonodo Sentinela
13.
J Dermatol ; 40(5): 393-5, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23488565

RESUMO

Angiolymphoid hyperplasia with eosinophilia (ALHE), also known as epithelioid hemangioma, is a benign vascular proliferation of uncertain etiology. Herein, we present the first documented case of ALHE following venipuncture and review the published work regarding the relationship of this entity to preceding trauma.


Assuntos
Hiperplasia Angiolinfoide com Eosinofilia/etiologia , Cateterismo/efeitos adversos , Flebotomia/efeitos adversos , Pele/patologia , Ferimentos e Lesões/complicações , Idoso de 80 Anos ou mais , Hiperplasia Angiolinfoide com Eosinofilia/patologia , Feminino , Humanos
16.
Pediatr Dermatol ; 26(3): 269-72, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19706086

RESUMO

Traditional therapy for pyogenic granuloma is procedural. In young children it can require a general anesthetic and may be complicated by scarring, dyspigmentation, and recurrence. We report a series of 10 children, highlighting the safety and efficacy of topical 5% Imiquimod as an alternative noninvasive treatment of pyogenic granuloma. Ten children with a mean age of 2.5 years and 10.8 week duration of facial pyogenic granuloma lesion were recruited. Treatment regime with topical Imiquimod 5% cream varied in frequency of application and duration according to clinical response. Clinical outcome in the majority of the children was satisfactory. Three had no evidence of disease and five had small hypopigmented or erythematous lesions which were continuing to improve and more acceptable then a surgical scar. One child required a prolonged treatment course, and one progressed to surgical excision when prolonged treatment failed. There were no systemic side effects noted in any of the patients and no recurrence noted with resolution sustained over an average of 9.6 months of follow-up. Imiquimod is a safe, cost-effective, and clinically effective management option in the treatment of pyogenic granuloma.


Assuntos
Adjuvantes Imunológicos/administração & dosagem , Aminoquinolinas/administração & dosagem , Dermatoses Faciais/tratamento farmacológico , Granuloma Piogênico/tratamento farmacológico , Administração Tópica , Criança , Pré-Escolar , Humanos , Imiquimode , Lactente
17.
Australas J Dermatol ; 48(4): 217-20, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17956478

RESUMO

We report the successful treatment of five children with facial pyogenic granuloma using topical imiquimod 5% cream. In all cases, resolution of the lesions was achieved within 2-4 weeks. Local erythema and scaling, consistent with a typical imiquimod response, was the most commonly observed side effect. No systemic complications were observed in any of the patients. There has been no recurrence of any of the lesions to date. Small mildly erythematous or hypopigmented macules remain at this stage of follow up.


Assuntos
Adjuvantes Imunológicos/administração & dosagem , Aminoquinolinas/administração & dosagem , Inibidores da Angiogênese/administração & dosagem , Granuloma Piogênico/tratamento farmacológico , Adjuvantes Imunológicos/efeitos adversos , Administração Tópica , Aminoquinolinas/efeitos adversos , Inibidores da Angiogênese/efeitos adversos , Pré-Escolar , Face/patologia , Feminino , Granuloma Piogênico/patologia , Humanos , Imiquimode , Lactente , Masculino , Pele/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA